LLY vs TTD: Which Is the Better Buy?
Side-by-side comparison of Eli Lilly and Company and The Trade Desk, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-26.
Eli Lilly and Company · Healthcare
$1,183.72
+2.1% upside to fair value
Med Conviction
Grade B
High Quality
VS
The Trade Desk, Inc. · Communication Services
$14.26
-1.8% upside to fair value
Med Conviction
Grade C
High Quality
QuantHub Verdict
LLY has more upside to fair value
(+2.1%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
LLY |
TTD |
| Current Price |
$1,183.72 |
$14.26 |
| Fair Value Estimate |
$1,208.00 |
$14.00 |
| Upside to Fair Value |
+2.1%
|
-1.8%
|
| Market Cap |
$1,114.8B |
$6.7B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
26.8x
|
7.5x
|
| Price / Sales |
14.0x
|
2.2x
|
| Price / FCF |
52.7x
|
7.8x
|
| Revenue Growth YoY |
+47.7%
|
+3.0%
|
| Gross Margin |
83.4%
|
83.0%
|
| Operating Margin |
49.7%
|
19.6%
|
| Return on Equity |
92.6%
|
16.1%
|
| Dividend Yield |
0.57% |
0% |
| FCF Yield |
1.9%
|
12.89%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Eli Lilly is a global pharmaceutical company whose incretin franchise, led by Mounjaro and Zepbound, has become the dominant growth engine in diabetes and obesity care. The business quality is high: TTM gross margin is 83.4%, TTM operating margin is 49.7%, TTM net margin is 33.5%, and ROE is 92.6%, while revenue grew 47.7% and earnings grew 25.3% in the most recent quarter on a year-over-year bas…
The Trade Desk operates a self-service, cloud-based demand-side platform that lets advertising agencies and their advertiser clients plan, buy and optimize data-driven digital campaigns across display, video, audio, native, social and connected TV, with 3,843 employees and a founder-led management team. Business quality is genuinely high on the unit economics: TTM gross margin of 83.0%, TTM opera…
Accumulation Zones
| Metric |
LLY |
TTD |
| Zone Low |
$906.00 |
$10.50 |
| Zone High |
$1,026.80 |
$11.90 |
| In Buy Zone? |
No
|
No
|